News

New drug enters Finland   July 2024

Medical Lead's customer Grifols brings a new subcutaneous immunoglobulin, Xembify^® to the Finnish market with support from Medical Lead Nordic. This will help patients suffering from primary immunodeficiency.

https://fimea.fi/en/databases_and_registers/fimeaweb?query=Xembify&humanmed=true&selfcare=true&receptmed=true&marketedmed=true&prefillonly=false

Medtech seminar   2024-05-08

Medical Lead's CEO Robert Harju-Jeanty gave an open seminar on Medtech for Moebio/Biocat in Barcelona.

https://www.biocat.cat/en/programs/short-program-2024-life-sciences-unveiling-future-health

Evaluator of EIT Health   October 2023

Robert Harju-Jeanty was for the fourth time invited as expert in the evaluator panel in the hearings of EU's grant applications of EIT Health, this time for digital Medtech.

https://eithealth.eu/opportunity/call-for-activities-related-to-the-flagships/

AgeTech market study and webinar   2023-02-21

Medical Lead finalised a study of the Swedish AgeTech market on the assignment of Business Finland to support Finnish companies to enter the Swedish market.

Webinar on internationalisation   2022-01-20

Medical Lead Nordic AB gave togehter with KTH a second webinar on the internationalisation roadmap for Medtech companies, assigned by Medtech4Health and Vinnova.

https://medtech4health.se/internationalisering/spelplan/

Entrepreneurship mentorship   2021

For the second time in Egypt, Medical Lead's CEO Robert Harju-Jeanty was mentor and lecturer for Clinical Innovation Fellowship program, supported by enpact, Research Institutes of Sweden and EIT Health.

https://enpact.org/entrepreneurial-support/accelerator/clinical-innovation-fellowship-egypt-2021/#/